Cambrex, the East Rutherford-based small molecule company, is investing more than $50 million to expand a manufacturing facility in Iowa, it announced this week.
The Charles City facility handles midscale and large-scale ingredient manufacturing, Cambrex said, and the expansion is intended to meet growing demand for small-molecule drug substance development and manufacturing.
This represents Cambrex’s sixth major investment at this site in the past eight years to meet customer needs, it noted.
“Small molecule manufacturing demand has been growing consistently over recent years, and this investment will enable Cambrex to continue to ccapitalize on this growth, further strengthening iour position as a market-leading (contract development and manufacturing organization),” Joe Nettleton, president of Cambrex’s Drug Substance Business Unit, said in a prepared statement. “This expansion in the U.S. for API manufacturing capacity comes at a time when our customers increasingly require high-quality partners to ensure reliable supply chains within the pharmaceutical sector.”
The expansion will add three large-scale work centers and one midscale work center, boosting site capacity by 30%. The expansion is scheduled to be operational in early 2022, and bring employment on site to more than 400 people.
